LivaNova delivers Q3 revenue of $393.1M, up 9.9%
Pontos principais
- LivaNova reported third-quarter 2026 revenue of $393.1 million, up 9.9% year over year, supported by growth in its medical technology businesses.
- Adjusted earnings increased to $1.23 per share from $1.11, while GAAP diluted earnings declined to $0.11 from $0.49.
- LivaNova raised its 2026 revenue growth guidance to 9%–10% at constant exchange rates and adjusted EPS guidance to $4.40–$4.50.
LivaNova (NASDAQ:LIVN) reported third-quarter 2026 revenue of $393.1 million, up 9.9% year over year, while raising its annual financial guidance.
Revenue increased from $357.8 million a year earlier, while adjusted diluted earnings rose to $1.23 per share from $1.11.
GAAP operating income declined to $28.4 million from $54 million, while adjusted operating income increased to $92.3 million from $80.4 million.
LivaNova raised its 2026 revenue growth forecast to 9%–10% and adjusted earnings guidance to $4.40–$4.50 per share.
Meanwhile, cardiopulmonary revenue increased 10.9% to $225.3 million, while Neuromodulation revenue rose 11.1% to $166.1 million, supported by higher sales volumes.
Operating cash flow reached $73.7 million, while LivaNova began operating a new oxygenator production line to expand manufacturing capacity.
